More on Illumina (ILMN): The stock is trading higher in the post session as its Q1 easily beats...

|By:, SA News Editor

More on Illumina (ILMN): The stock is trading higher in the post session as its Q1 easily beats across the board on a 21% jump in revenue Y/Y. The company swung to a net loss for the quarter however, after taking nearly a $107M loss related to its unfavorable verdict in its patent litigation with Syntrix Biosystems. R&D and SG&A expenses were both higher as a percentage of revenue, while margins were relatively flat compared to the prior year. Shares +4.3% AH.